Categories Analysis, Earnings, Health Care

Earnings preview: Merck to ride the wave of expanding oncology portfolio in Q4

The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict the company will post revenues of $10.95 billion, representing a 5% annual increase, when it announces the December-quarter results Friday before the opening bell.

Like many of its peers, Merck has been pushing its oncology portfolio aggressively with focus on Lynparza, Lenvima and Keytruda, which are considered to be among the most successful cancer therapies in the US. The popularity of Keytruda, especially after recent trials confirmed its effectiveness in treating multiple types of cancer, is expected to have a positive effect on the top-line performance this time. The other main business divisions, vaccines and animal health, also continue to be growth drivers.

Like many of its peers, Merck has been pushing its oncology portfolio aggressively with focus on Lynparza, Lenvima and Keytruda

In the next two years, the Kenilworth, New Jersey-based company will be expanding its production capacity, mainly in oncology and animal health, with an estimated investment of about $16 billion. It is expected that there will be an increase in R&D expenses in the fourth quarter, reflecting the management’s initiatives to revive research and development activities in the core areas of the business.

Merck third quarter 2018 Earnings Infographic
Merck Co. Q3 2018 Earnings Infographic

In the third quarter, the pharma giant’s revenues moved up 5% year-over-year to $10.8 billion but came in below expectations. Meanwhile, adjusted earnings climbed 7.2% to $1.19 per share, beating estimates. Revenues from the vaccine business grew 13% mainly due to the growing demand for Gardasil in the overseas market.

Also Read:  Humana (HUM) can offer long-term returns despite high valuation

Currently, the average analysts’ rating on Merck is buy. The positive recommendation and the increased price target of $81 make the stock an investment option worth considering.

Related: Merck & Co. Q3 2018 Earnings Conference Call Transcript

Among Merck’s peers, Eli Lilly (LLY) is scheduled to release its fourth quarter results on February 13 before the market opens. Last week, AbbVie (ABBV) reported weaker than expected earnings for the most recent quarter – despite a marked increase in revenues – hurt mainly by acquisition-related charges.

Merck’s stock climbed to a seven-year high last month, after rising steadily throughout 2018. The stock, which gained about 25% in the past twelve months, traded slightly lower during Wednesday’s regular session.


Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Major earnings conferences to watch this week

After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the

Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why

Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so

The COVID-19 pandemic gave these companies an unexpected opportunity

The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results